BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 38052492)

  • 1. Novel Anti-Mesothelin Nanobodies and Recombinant Immunotoxins with
    Nguyen MQ; Kim DH; Shim HJ; Ta HKK; Vu TL; Nguyen TKO; Lim JC; Choe H
    Mol Cells; 2023 Dec; 46(12):764-777. PubMed ID: 38052492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Designing the furin-cleavable linker in recombinant immunotoxins based on Pseudomonas exotoxin A.
    Weldon JE; Skarzynski M; Therres JA; Ostovitz JR; Zhou H; Kreitman RJ; Pastan I
    Bioconjug Chem; 2015 Jun; 26(6):1120-8. PubMed ID: 25997032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble Cytoplasmic Expression and Purification of Immunotoxin HER2(scFv)-PE24B as a Maltose Binding Protein Fusion.
    Park S; Nguyen MQ; Ta HKK; Nguyen MT; Lee G; Kim CJ; Jang YJ; Choe H
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34204265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modular Conjugation of a Potent Anti-HER2 Immunotoxin Using Coassociating Peptides.
    Stoessel A; Groysbeck N; Guyot L; Barret L; Nominé Y; Nguekeu-Zebaze L; Bender A; Voilquin L; Lutz T; Pallaoro N; Blocat M; Deville C; Masson M; Zuber G; Chatton B; Donzeau M
    Bioconjug Chem; 2020 Oct; 31(10):2421-2430. PubMed ID: 32996763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protection of the Furin Cleavage Site in Low-Toxicity Immunotoxins Based on Pseudomonas Exotoxin A.
    Kaplan G; Lee F; Onda M; Kolyvas E; Bhardwaj G; Baker D; Pastan I
    Toxins (Basel); 2016 Jul; 8(8):. PubMed ID: 27463727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-Mesothelin Recombinant Immunotoxin Therapy for Colorectal Cancer.
    Cerise A; Bera TK; Liu X; Wei J; Pastan I
    Clin Colorectal Cancer; 2019 Sep; 18(3):192-199.e1. PubMed ID: 31345777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticancer Effects of Mesothelin-Targeted Immunotoxin Therapy Are Regulated by Tyrosine Kinase DDR1.
    Ali-Rahmani F; FitzGerald DJ; Martin S; Patel P; Prunotto M; Ormanoglu P; Thomas C; Pastan I
    Cancer Res; 2016 Mar; 76(6):1560-8. PubMed ID: 26719540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity of therapeutic recombinant immunotoxins.
    Mazor R; Onda M; Pastan I
    Immunol Rev; 2016 Mar; 270(1):152-64. PubMed ID: 26864110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic comparison of single-chain Fv antibody-fusion toxin constructs containing Pseudomonas Exotoxin A or saporin produced in different microbial expression systems.
    Della Cristina P; Castagna M; Lombardi A; Barison E; Tagliabue G; Ceriotti A; Koutris I; Di Leandro L; Giansanti F; Vago R; Ippoliti R; Flavell SU; Flavell DJ; Colombatti M; Fabbrini MS
    Microb Cell Fact; 2015 Feb; 14():19. PubMed ID: 25889802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of Potent Anti-HER1/2 Immunotoxins by Protein Ligation Using Split Inteins.
    Pirzer T; Becher KS; Rieker M; Meckel T; Mootz HD; Kolmar H
    ACS Chem Biol; 2018 Aug; 13(8):2058-2066. PubMed ID: 29920062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving the
    Kaplan G; Mazor R; Lee F; Jang Y; Leshem Y; Pastan I
    Mol Cancer Ther; 2018 Jul; 17(7):1486-1493. PubMed ID: 29695631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineered Anti-GPC3 Immunotoxin, HN3-ABD-T20, Produces Regression in Mouse Liver Cancer Xenografts Through Prolonged Serum Retention.
    Fleming BD; Urban DJ; Hall MD; Longerich T; Greten TF; Pastan I; Ho M
    Hepatology; 2020 May; 71(5):1696-1711. PubMed ID: 31520528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotoxin-mediated targeting of claudin-4 inhibits the proliferation of cancer cells.
    Hashimi SM; Yu S; Alqurashi N; Ipe DS; Wei MQ
    Int J Oncol; 2013 Jun; 42(6):1911-8. PubMed ID: 23563899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bivalent disulfide-stabilized fragment variable immunotoxin directed against mesotheliomas and ovarian cancer.
    Bera TK; Williams-Gould J; Beers R; Chowdhury P; Pastan I
    Mol Cancer Ther; 2001 Dec; 1(2):79-84. PubMed ID: 12467225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation of Single-Domain Antibody-Based Recombinant Immunotoxins.
    Fleming BD; Ho M
    Methods Mol Biol; 2022; 2446():489-512. PubMed ID: 35157290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design of a modular immunotoxin connected by polyionic adapter peptides.
    Kleinschmidt M; Rudolph R; Lilie H
    J Mol Biol; 2003 Mar; 327(2):445-52. PubMed ID: 12628249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methylation-associated partial down-regulation of mesothelin causes resistance to anti-mesothelin immunotoxins in a pancreatic cancer cell line.
    Hollevoet K; Mason-Osann E; Müller F; Pastan I
    PLoS One; 2015; 10(3):e0122462. PubMed ID: 25803818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The immunotoxin activity of exotoxin A is sensitive to domain modifications.
    Amiri Tehranizadeh Z; Sankian M; Fazly Bazzaz BS; Chamani J; Mehri S; Baratian A; Saberi MR
    Int J Biol Macromol; 2019 Aug; 134():1120-1131. PubMed ID: 31129209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Affitoxin--a novel recombinant, HER2-specific, anticancer agent for targeted therapy of HER2-positive tumors.
    Zielinski R; Lyakhov I; Jacobs A; Chertov O; Kramer-Marek G; Francella N; Stephen A; Fisher R; Blumenthal R; Capala J
    J Immunother; 2009 Oct; 32(8):817-25. PubMed ID: 19752752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humanized CD7 nanobody-based immunotoxins exhibit promising anti-T-cell acute lymphoblastic leukemia potential.
    Yu Y; Li J; Zhu X; Tang X; Bao Y; Sun X; Huang Y; Tian F; Liu X; Yang L
    Int J Nanomedicine; 2017; 12():1969-1983. PubMed ID: 28331319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.